Newswise — The study reveals an important route through which fascin promotes cancer development and provides insights into potential pathways that could block its action.
Fascin is known to control the structures that allow cells to move – specifically the assembly of bundles of a protein called actin, which create the tiny ‘legs’ that cancer cells use to migrate to distant sites within the body. Fascin is also known to be at much higher levels in most solid tumours, where it helps cancer cells migrate and invade into other tissues. This invasion - or ‘metastasis’ - of tumour cells is the main reason why many cancers are so hard to treat
“We have previously shown that fascin resides in the control centre of the cell – the nucleus – at certain times in the cell’s growth cycle,” explains lead author Campbell Lawson, Research Associate at the Randall Centre for Cell and Molecular Biophysics, King’s College London, UK. “However, it was not known how fascin’s movement or function within the nucleus are controlled, and this hinders our ability to develop treatments that block its role in promoting cancer growth and spread.”
To understand fascin further, the team created a series of cancer cell lines with and without functional fascin, as well as a suite of fascin ‘nanobodies’ labelled with fluorescent markers, to alter its location in cells and explore its interactions with other proteins in the nucleus.
They found that fascin is actively transported in and out of the nucleus and, once there, it supports the assembly of actin bundles. Indeed, cells without fascin were unable to build nuclear actin bundles to the same extent. Fascin also interacted with another group of important proteins in the cell nucleus, called histones. When fascin is not involved in bundling actin, it is bound to histone H3 – an important player involved in organising DNA within the nucleus.
Given the interaction of fascin with histones, the team looked at whether fascin was also involved in DNA repair processes in cancer cells, which helps them to survive. They found DNA repair was impaired in cells lacking fascin, indicating that the protein might be required for cancer cells to trigger their response to DNA damage caused by chemo- or radiotherapy. Fascin-depleted cells also had changes to their chromatin structure – the way the DNA is packaged in the cell – compared to cells with normal fascin levels.
Although nuclear fascin plays an important role in nuclear actin assembly, DNA structure and repair, it is also important in the cell cytoplasm, where it helps cancer cells build tiny appendages called filopodia, which promote invasion. So the team wanted to understand whether moving all fascin into the nucleus would prevent the cytoplasmic function of fascin. As they anticipated, in cells with enhanced nuclear fascin, the number of filopodia was significantly reduced because there was no fascin in the cytoplasm to support assembly of these structures. The cells also invaded less into 3-dimensional scaffolds that mimic the tissue surrounding tumours. Importantly, cells that had forced nuclear fascin had significantly reduced growth rates and viability because they assembled large stable actin bundles in the nucleus which prevented them from going through the cell cycle. Collectively, these results indicate that, rather than trying to find ways to block fascin, forcing it all into the nucleus of cancer cells could prevent their growth and movement.
“Our study provides insights into a new role for fascin in controlling nuclear actin bundling to support tumour cell viability,” concludes senior author Maddy Parsons, Professor of Cell Biology at the Randall Centre for Cell and Molecular Biophysics, King’s College London. “Given fascin is at very high levels in many solid tumours, but not in normal tissues, this molecule is an interesting therapeutic target. We propose that promoting fascin accumulation in the nucleus of cancer cells, rather than only focusing on targeting it in the cell cytoplasm, could be an alternative approach that would prevent both tumour growth and spread.”
##
About eLife
eLife transforms research communication to create a future where a diverse, global community of scientists and researchers produces open and trusted results for the benefit of all. Independent, not-for-profit and supported by funders, we improve the way science is practised and shared. From the research we publish, to the tools we build, to the people we work with, we’ve earned a reputation for quality, integrity and the flexibility to bring about real change. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest Cancer Biology research published in eLife, visit https://elifesciences.org/subjects/cancer-biology.
And for the latest in Cell Biology, see https://elifesciences.org/subjects/cell-biology.
King’s College London
King's College London is one of the top 35 UK universities in the world and one of the top 10 in Europe (QS World University Rankings, 2020/21) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff.
King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2021 Research Excellence Framework (REF), King’s maintained its sixth position for ‘research power’ in the UK. King’s has also been rated third amongst multidisciplinary institutions for impact, with 67.8% of its research impact rated outstanding.
Since our foundation, King’s students and staff have dedicated themselves in the service of society. King’s will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King's strategic vision to take the university to the 200th anniversary of its founding.
RSS